Movement Alert｜HJ Science-B Falls 9.37% in Regular Trading, Cumulative Decline Exceeds 50% Since IPO

Market Focus

7 hours ago

On July 3, HJ Science-B fell 9.37% in regular trading, trading at HK$37.58 per share, with turnover of HK$907,100.

The stock continues to face sustained selling pressure since its Hong Kong listing on June 23, when it debuted at HK$81.80 per share. Shares collapsed 56.89% on the first trading day and have remained in a low-range consolidation since, with cumulative losses now exceeding 50% from the IPO price.

As a clinical-stage biotech listed under Chapter 18A of the Hong Kong Exchange, HJ Science currently has no products approved for commercial sale. Its core pipeline candidates — HJ787, HJ178, and HJ891 — are all in clinical development stages, facing intense competition across their respective therapeutic areas. The company reported revenue of approximately RMB 1.8 million for the year ended December 2024, against R&D expenses of RMB 74.97 million and a net loss of RMB 202.3 million.

HJ Science was co-founded by a team of doctoral-level experts and focuses on the research and development of innovative therapies for oncology, autoimmune, and metabolic diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130289872"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130289872\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130289872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130289872","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HJ Science-B Falls 9.37% in Regular Trading, Cumulative Decline Exceeds 50% Since IPO","media":"Market Focus","content":"<p><p>On July 3, HJ Science-B fell 9.37% in regular trading, trading at HK$37.58 per share, with turnover of HK$907,100.</p><p>The stock continues to face sustained selling pressure since its Hong Kong listing on June 23, when it debuted at HK$81.80 per share. Shares collapsed 56.89% on the first trading day and have remained in a low-range consolidation since, with cumulative losses now exceeding 50% from the IPO price.</p><p>As a clinical-stage biotech listed under Chapter 18A of the Hong Kong Exchange, HJ Science currently has no products approved for commercial sale. Its core pipeline candidates — HJ787, HJ178, and HJ891 — are all in clinical development stages, facing intense competition across their respective therapeutic areas. The company reported revenue of approximately RMB 1.8 million for the year ended December 2024, against R&D expenses of RMB 74.97 million and a net loss of RMB 202.3 million.</p><p>HJ Science was co-founded by a team of doctoral-level experts and focuses on the research and development of innovative therapies for oncology, autoimmune, and metabolic diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HJ Science-B Falls 9.37% in Regular Trading, Cumulative Decline Exceeds 50% Since IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HJ Science-B Falls 9.37% in Regular Trading, Cumulative Decline Exceeds 50% Since IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, HJ Science-B fell 9.37% in regular trading, trading at HK$37.58 per share, with turnover of HK$907,100.</p><p>The stock continues to face sustained selling pressure since its Hong Kong listing on June 23, when it debuted at HK$81.80 per share. Shares collapsed 56.89% on the first trading day and have remained in a low-range consolidation since, with cumulative losses now exceeding 50% from the IPO price.</p><p>As a clinical-stage biotech listed under Chapter 18A of the Hong Kong Exchange, HJ Science currently has no products approved for commercial sale. Its core pipeline candidates — HJ787, HJ178, and HJ891 — are all in clinical development stages, facing intense competition across their respective therapeutic areas. The company reported revenue of approximately RMB 1.8 million for the year ended December 2024, against R&D expenses of RMB 74.97 million and a net loss of RMB 202.3 million.</p><p>HJ Science was co-founded by a team of doctoral-level experts and focuses on the research and development of innovative therapies for oncology, autoimmune, and metabolic diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06132","symbol_name":"华健未来-B","start_time":0,"source_url":"","article_id":"1130289872","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130289872","pubTimestamp":1783045086,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, HJ Science-B fell 9.37% in regular trading, trading at HK$37.58 per share, with turnover of HK$907,100.The stock continues to face sustained selling pressure since its Hong Kong listing on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06132":"华健未来-B"},"translate_title":"异动快讯|HJ Science-B常规交易跌9.37%IPO以来累计跌幅超50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06132":1},"content_text":"On July 3, HJ Science-B fell 9.37% in regular trading, trading at HK$37.58 per share, with turnover of HK$907,100.The stock continues to face sustained selling pressure since its Hong Kong listing on June 23, when it debuted at HK$81.80 per share. Shares collapsed 56.89% on the first trading day and have remained in a low-range consolidation since, with cumulative losses now exceeding 50% from the IPO price.As a clinical-stage biotech listed under Chapter 18A of the Hong Kong Exchange, HJ Science currently has no products approved for commercial sale. Its core pipeline candidates — HJ787, HJ178, and HJ891 — are all in clinical development stages, facing intense competition across their respective therapeutic areas. The company reported revenue of approximately RMB 1.8 million for the year ended December 2024, against R&D expenses of RMB 74.97 million and a net loss of RMB 202.3 million.HJ Science was co-founded by a team of doctoral-level experts and focuses on the research and development of innovative therapies for oncology, autoimmune, and metabolic diseases.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}